Clinical data for a fish-oil-based drug from Amarin Corporation confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.
Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.
Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.
AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
In Amarin’s REDUCE-IT clinical trial of 8,179 statin-treated adults with increased risk of cardiovascular problems, the drug showed a 25 percent relative risk reduction in major adverse cardiovascular events compared to placebo.
Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.
Janssen Pharmaceuticals halted the company’s Phase III chronic kidney disease trial for Invokana early due to the fact that the SGLT2 diabetes drug had already achieved pre-specified efficacy data.
Eisai Announces Positive Topline Results from Large-Scale Cardiovascular Outcome Trial for Anti-Obesity Agent Belviq
Eisai Inc. announced positive top-line results from the CAMELLIA-TIMI 61 cardiovascular outcome trial.
The U.S. Food and Drug Administration issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve.
The U.S. FDA approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, which will square off against established drugs in the market.
Carmel Biosciences Inc. received final approval of its New Drug Application from the U.S. Food and Drug Administration for Prexxartan (valsartan) oral solution.
Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.
Novartis’ canakinumab reduced cardiovascular risk by 25 percent in subgroup of CANTOS Phase III trial participants
Novartis announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association (AHA) Scientific Sessions 2017 and published simultaneously in The Lancet.
Stopping low-dose aspirin therapy without good reason raises the likelihood of heart attack or stroke by nearly 40 percent, a large Swedish study suggests.
AstraZeneca agreed to sell the U.S. rights to a portfolio of anesthetics to South Africa’s Aspen Group.
An anti-inflammatory drug developed for cardiac patients has an exciting, yet unintended side effect – possible prevention of lung cancer.
The FDA approved an expanded use of Novo Nordisk’s diabetes drug Victoza to reduce the risk of cardiovascular events such as heart attack and stroke.
Amgen announced that the New England Journal of Medicine published results from the Repatha (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).
Roche’s seven-year-old rheumatoid arthritis drug Actemra is being linked to hundreds of deaths due to undisclosed side effects.
Shares of Capricor Therapeutics plunged nearly 60 percent in premarket trading after the company announced it was laying off an unknown number of employees following the failure of a mid-stage cardiovascular drug trial.